Merck in the news

AbbVie's dividend is preferred over Merck's for retirees due to higher yield, faster growth, and having passed its patent cliff, despite Merck's stronger dividend cushion.

JPMorgan increased Merck's price target to $165 from $150, keeping an Overweight rating, ahead of Q3 earnings and anticipating strong pipeline data for lung cancer and melanoma treatments.

Merck's experimental drug tulisokibart demonstrated strong efficacy and a favorable dosing schedule in a mid-stage trial for chronic skin disease.

Merck KGaA's EMD Electronics business unit opened a 38,000-square-foot R&D facility in Sheboygan Falls, creating 44 new jobs.

Moderna and Merck's collaboration on a personalized mRNA cancer vaccine faces market hype and valuation concerns.

Moderna and Merck's cancer vaccine significantly reduced melanoma recurrence in a recent study, generating excitement among experts.

Merck's anti-TL1A antibody tulisokibart showed positive phase 2b results in a trial for moderate to severe hidradenitis suppurativa, meeting primary and secondary endpoints.

Merck's stock dipped more than the broader market, with its valuation metrics like Forward P/E and PEG ratios indicating a premium compared to industry averages, and upcoming earnings expected to show a decline in EPS.

Merck's stock underperformed the broader market, with upcoming earnings expected to show a drop in EPS despite revenue growth, and it trades at a premium valuation.

Merck is pulling its antibiotic Recarbrio from the US market due to portfolio review, raising concerns about the financial viability of new antibiotics for multidrug-resistant infections.

Merck and Daiichi Sankyo withdrew their accelerated approval application for lung cancer drug ifinatamab deruxtecan because the FDA found their data package didn't meet requirements.

AstraZeneca invested in Summit Therapeutics to advance Akeso's cancer drug ivonescimab, showcasing growth in the Chinese biotech sector.

Merck acquired exclusive global rights to SciBrunch Therapeutics' preclinical oral KRAS-inhibiting molecular glue, SPR2015, in a deal worth up to $2.13 billion, aiming to strengthen its oncology pipeline.

Merck is pulling its antibacterial drug Recarbrio from the U.S. market, citing portfolio review rather than safety issues, raising concerns about the future of new antibiotic development.

Merck and Daiichi Sankyo withdrew their FDA application for a B7-H3 antibody-drug conjugate for lung cancer.

Daiichi Sankyo and Merck withdrew their application for accelerated FDA approval of I-DXd for extensive-stage small cell lung cancer due to insufficient data for that pathway.

Merck stopped selling the antibiotic Recarbrio in the U.S., a drug used for serious infections but with limited market potential due to its last-resort designation.

Merck's new drug for diabetic macular edema shows promising efficacy but raises safety concerns, as the company prepares for KEYTRUDA's patent expiration and faces narrowing financial flexibility.

Merck expanded its oncology pipeline with a $400 million acquisition of SciBrunch's KRAS G12D inhibitor, SPR2015, while facing a setback with the withdrawn accelerated FDA approval application for its lung cancer drug, I-DXd, developed with Daiichi Sankyo.

Merck and Daiichi Sankyo withdrew their accelerated approval application for a lung cancer drug after the FDA found the data insufficient, impacting their $4 billion partnership.